Lin, Sheng-Li <br/><br/>
ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.  [electronic resource] 

 -  PloS one  Feb 2010 
 - e9013 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0009013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alternative Splicing<br/>Antineoplastic Agents, Hormonal--pharmacology<br/>Blotting, Western<br/>Butadienes--pharmacology<br/>Cell Line, Tumor<br/>Cell Membrane--metabolism<br/>Cell Proliferation--drug effects<br/>Chromones--pharmacology<br/>Dose-Response Relationship, Drug<br/>Endometrial Neoplasms--genetics<br/>Enzyme Activation--drug effects<br/>Estrogen Receptor alpha--agonists<br/>Estrogens--pharmacology<br/>Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors<br/>Female<br/>Humans<br/>Morpholines--pharmacology<br/>Nitriles--pharmacology<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Isoforms--agonists<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Proto-Oncogene Proteins c-myc--metabolism<br/>RNA Interference<br/>Signal Transduction--drug effects<br/>Tamoxifen--pharmacology